3. The use according to claim 1 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to claim 2, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.

4. The use according to claim 1 or 3 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to claim 2 or 3, wherein the subject is a human or an animal.

5. The use according to any one of claims 1, 3 and 4 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to any one of claims 2-4, wherein the adoptive cell therapeutic composition and oncolytic viral vectors coding for at least one cytokine are to be administered to a subject simultaneously or consecutively, in any order.

6. The use according to claim 5 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to claim 5, wherein there is a time period of one minute to four weeks between the consecutive administration of adoptive cell therapeutic composition and oncolytic viral vectors coding for at least one cytokine and/or there are several administrations of adoptive cell therapeutic composition and oncolytic viral vectors.

7. The use according to any one of claims 1 and 3-6 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to any one of claims 2-6, wherein the adoptive cell therapeutic composition and/or oncolytic viral vectors coding for at least one cytokine are to be administered through an intratumoral, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration.

8. The use according to any one of claims 1 and 3-7 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to any one of claims 2-7, wherein the oncolytic viral vector codes for two or more cytokines.

9. The use according to claim 8 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to claim 8, wherein the second or further cytokines is/are selected from a cytokine group consisting of interferon alpha, interferon beta, interferon gamma, complement C5a, GMCSF, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5 (=RANTES), CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12,

CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2, or the oncolytic viral vector codes for IL-2 and a cytokine or cytokines selected from a cytokine group consisting of interferon alpha, interferon beta, interferon gamma, complement C5a, GMCSF, TNFalpha, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2.

10. The use according to claim 8 or 9 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to claim 8 or 9, wherein the adenoviral vector comprises an internal ribosomal entry site (IRES) or a ribosome shunt site 2A between the two transgenes.

11. The use according to any one of claims 1 and 3-10 or the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to any one of claims 2-10, wherein oncolytic adenoviral vectors coding for at least one cytokine is to be administered in an amount of $1x10^{10}$- $1x10^{14}$ virus particles.

12. An oncolytic adenoviral vector for use in increasing the efficacy of separate adoptive T-cell therapy in a tumor of a subject, wherein said oncolytic adenoviral vector is an adenovirus serotype 5 (Ad5) vector comprising

- a 5/3 chimeric fiber knob,
- E2F1 promoter for tumor specific expression of E1A,
- a 24 bp deletion (D24) in the Rb binding constant region 2 of adenoviral E1,
- a nucleic acid sequence deletion of viral gp19k and 6.7k reading frames, and
- a nucleic acid sequence encoding at least TNFalpha or IL-2 transgene in the place of the deleted gp19k/6.7K in the E3 region resulting in replication-associated control of transgene expression under the viral E3 promoter.

oncolytic adenoviral vector codes for IL-2 and a cytokine or cytokines selected from the second cytokine group of claim 9.

19. The oncolytic adenoviral vector according to claim 17 or 18, wherein it comprises an internal ribosomal entry site (IRES) or optionally a ribosome shunt site 2A between the two transgenes.

20. The oncolytic adenoviral vector according to any one of claims 17-19, wherein the promoter for expression of a transgene in the E3 region is the CMV or E2F promoter.

21. A pharmaceutical composition comprising an oncolytic vector according to any one of claims 16-20.

22. Use of an oncolytic adenoviral vector according to any one of claims 16-20 in the manufacture of a medicament for treating cancer in a subject in need thereof.

23. An oncolytic adenoviral vector according to any one of claims 16-20 for use in treatment of cancer.

24. The use according to any one of claims 1, 3-11, 13 and 22, the oncolytic adenoviral vector coding for at least one cytokine together with a separate adoptive T-cell therapeutic composition for use according to any one of claims 2-11, or the oncolytic adenoviral vector for use according to claim 23, wherein the oncolytic adenoviral vector is to be administered with concurrent or sequential radiotherapy, monoclonal antibodies, chemotherapy or other anti-cancer drugs or interventions to a subject.